This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating bromodomain inhibition in pulmonary arterial hypertension might be feasible. They also aimed to provide preliminary evidence that apabetalone may be safe and effective in PAH.
top of page
Recent Posts
Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...
In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...
A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...
bottom of page
Comentarios